Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
作者信息
Mahil S K, Yiu Z Z N, Mason K J, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan S M, Di Meglio P, Musters A H, Prieto-Merino D, Tsakok T, Warren R B, Flohr C, Spuls P I, Griffiths C E M, Barker J, Irvine A D, Smith C H
机构信息
St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK.
出版信息
Br J Dermatol. 2020 Aug;183(2):404-406. doi: 10.1111/bjd.19161. Epub 2020 Jun 10.
Abstract
摘要
相似文献
1
Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.银屑病和特应性皮炎中新型冠状病毒肺炎病例的全球报告：大流行期间为医疗护理提供信息的一个契机。
Br J Dermatol. 2020 Aug;183(2):404-406. doi: 10.1111/bjd.19161. Epub 2020 Jun 10.
2
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.评估在2019冠状病毒病大流行期间使用度普利尤单抗治疗特应性皮炎的风险。
J Am Acad Dermatol. 2020 Sep;83(3):e251-e252. doi: 10.1016/j.jaad.2020.06.015. Epub 2020 Jun 10.
3
Global Hidradenitis Suppurativa COVID-19 Registry: a registry to inform data-driven management practices.全球化脓性汗腺炎新型冠状病毒肺炎登记处：一个为基于数据的管理实践提供信息的登记处。
Br J Dermatol. 2020 Oct;183(4):780-781. doi: 10.1111/bjd.19345. Epub 2020 Aug 2.
4
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.2019年冠状病毒病大流行对接受生物疗法治疗的慢性斑块状银屑病患者的影响：意大利北部的经验。
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
5
Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study.2019年冠状病毒病大流行期间接受生物治疗的银屑病患者的治疗中断情况及疾病传播率：一项加拿大多中心回顾性研究
J Am Acad Dermatol. 2020 Oct;83(4):1212-1214. doi: 10.1016/j.jaad.2020.07.021. Epub 2020 Jul 15.
6
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.一名使用司库奇尤单抗治疗的银屑病患者发生的复杂型2019冠状病毒病（COVID-19）
Int J Dermatol. 2020 Aug;59(8):e267-e268. doi: 10.1111/ijd.15008. Epub 2020 Jun 18.
7
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.接受白细胞介素17通路抑制生物制剂治疗的银屑病患者发生呼吸道感染和症状的风险：对COVID-19大流行期间决策相关关键试验的荟萃估计。
J Am Acad Dermatol. 2020 Aug;83(2):677-679. doi: 10.1016/j.jaad.2020.05.035. Epub 2020 May 19.
8
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.特罗华：胸科癌症国际 COVID-19 合作组织。
Cancer Cell. 2020 Jun 8;37(6):742-745. doi: 10.1016/j.ccell.2020.05.008. Epub 2020 May 16.
9
Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.主动疗法联合被动免疫疗法可能对对抗新冠病毒有效。
Clin Transl Sci. 2020 Sep;13(5):835-837. doi: 10.1111/cts.12816. Epub 2020 Jun 26.
10
COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy.新型冠状病毒肺炎与银屑病生物制剂：高流行地区的经验——意大利伦巴第大区贝加莫市
J Am Acad Dermatol. 2020 Jul;83(1):292-294. doi: 10.1016/j.jaad.2020.04.165. Epub 2020 May 6.
引用本文的文献
1
Navigating patients with atopic dermatitis or chronic spontaneous urticaria during the COVID-19 pandemic.在新冠疫情期间为特应性皮炎或慢性自发性荨麻疹患者提供指导。
Front Allergy. 2022 Oct 4;3:809646. doi: 10.3389/falgy.2022.809646. eCollection 2022.
2
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.意大利 COVID-19 大流行期间接受全身治疗的特应性皮炎患者的管理：来自 DA-COVID-19 登记处的数据。
Allergy. 2021 Jun;76(6):1813-1824. doi: 10.1111/all.14767. Epub 2021 Mar 9.
3
Shedding light on therapeutics in alopecia and their relevance to COVID-19.揭示脱发治疗方法及其与COVID-19的相关性。
Clin Dermatol. 2021 Jan-Feb;39(1):76-83. doi: 10.1016/j.clindermatol.2020.12.015. Epub 2020 Dec 16.
4
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?2019年冠状病毒病大流行对慢性炎症性免疫介导性皮肤病病程及管理的影响：有哪些证据？
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
5
The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding?新冠病毒与自身免疫的交叉点：我们目前的理解是什么？
Pathog Immun. 2021 Mar 8;6(1):31-54. doi: 10.20411/pai.v6i1.417. eCollection 2021.
6
Biologics for Psoriasis during the COVID-19 Pandemic.新冠疫情期间用于治疗银屑病的生物制剂
J Clin Med. 2021 Mar 30;10(7):1390. doi: 10.3390/jcm10071390.
7
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies.通过流行病学和基因组研究确定的 COVID-19 与皮肤状况之间的关联。
J Allergy Clin Immunol. 2021 Mar;147(3):857-869.e7. doi: 10.1016/j.jaci.2021.01.006. Epub 2021 Jan 21.
8
The impact of COVID-19 pandemic on the management of patients with chronic urticaria: An observational two-center study from Turkey.COVID-19 大流行对慢性荨麻疹患者管理的影响：来自土耳其的一项观察性两中心研究。
Dermatol Ther. 2021 Jan;34(1):e14652. doi: 10.1111/dth.14652. Epub 2020 Dec 19.
9
Skin manifestations of COVID-19 in children: Part 3.儿童 COVID-19 皮肤表现：第 3 部分。
Clin Exp Dermatol. 2021 Apr;46(3):462-472. doi: 10.1111/ced.14483. Epub 2020 Nov 18.
10
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.与银屑病患者 COVID-19 不良结局相关的因素：一项基于全球注册研究的分析。
J Allergy Clin Immunol. 2021 Jan;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007. Epub 2020 Oct 16.
本文引用的文献
1
COVID-19: immunopathology and its implications for therapy.新型冠状病毒肺炎：免疫病理学及其治疗意义。
Nat Rev Immunol. 2020 May;20(5):269-270. doi: 10.1038/s41577-020-0308-3.
2
Baricitinib for COVID-19: a suitable treatment?巴瑞替尼用于治疗新冠肺炎：一种合适的治疗方法？
Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3.
3
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis.欧洲特应性皮炎工作组关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染与特应性皮炎的声明。
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e241-e242. doi: 10.1111/jdv.16411.
4
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
5
Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis.成人特应性皮炎患者系统免疫调节药物的安全性比较。
J Am Acad Dermatol. 2021 Aug;85(2):321-329. doi: 10.1016/j.jaad.2019.05.073. Epub 2019 May 31.
6
Atopic dermatitis.特应性皮炎。
Nat Rev Dis Primers. 2018 Jun 21;4(1):1. doi: 10.1038/s41572-018-0001-z.
7
Update on psoriasis immunopathogenesis and targeted immunotherapy.银屑病免疫发病机制及靶向免疫治疗的最新进展
Semin Immunopathol. 2016 Jan;38(1):11-27. doi: 10.1007/s00281-015-0539-8. Epub 2015 Nov 16.
8
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).银屑病的生物制剂和系统治疗的严重感染风险：来自银屑病纵向评估和登记研究（PSOLAR）的结果。
JAMA Dermatol. 2015 Sep;151(9):961-9. doi: 10.1001/jamadermatol.2015.0718.
Zotero 插件